Treatment for Multiple Myeloma - Researching Potential Drug Candidates

In the United States alone, almost 36,000 individuals are expected to be diagnosed with multiple myeloma this year, and sadly, over 12,000 people will lose their lives to this devastating disease. Multiple myeloma currently has no cure, and the 5-year survival rate in the US stands at 55%. 

This is why the search for effective therapeutic agents is of utmost importance. Eric Wang, an associate professor in the Department of Pharmaceutical Sciences at PCOM School of Pharmacy, is dedicated to finding potential drug candidates for the treatment of multiple myeloma. His research focuses on identifying therapeutic agents that can target cancer cells while sparing normal cells. 

To achieve this, Dr. Wang and his team are exploring new compounds from natural sources. They are using advanced techniques like 3D bioprinting to create realistic models for screening drug candidates, going beyond the limitations of traditional 2D cell culture methods. 

Understanding multiple myeloma is crucial in developing effective treatments. This type of cancer affects plasma cells in the bone marrow, which produce antibodies to fight infection. In multiple myeloma patients, these plasma cells produce abnormal proteins that can damage various organs, including the bones and kidneys. As the disease progresses, symptoms may include bone pain, fatigue, weakness, and an increased susceptibility to infections. 

Treatment options for multiple myeloma depend on various factors such as age, overall health, and the disease's stage. It may involve chemotherapy, radiation therapy, targeted therapy, bone marrow transplant, or a combination of these approaches. Multiple myeloma can lead to complications that can ultimately be fatal. The abnormal proteins produced by cancer cells can cause kidney failure. Additionally, weakened immune systems make it difficult for patients to fight off life-threatening infections. In some cases, multiple myeloma may give rise to secondary cancers like leukemia or lymphoma. 

Despite being a serious condition, managing multiple myeloma is possible with proper treatment and care. Early detection and treatment can significantly improve the outlook for individuals diagnosed with this disease. 

Eric Wang's commitment to research stems from his mother, a former professor and researcher in pharmaceutical sciences. He values dedication, passion, and commitment to research and brings these qualities to his work as a faculty researcher at PCOM. Dr. Wang appreciates the exceptional research experience provided by PCOM, which includes internal funding and a dedicated research team. He also mentors students, particularly those pursuing student research opportunities in the Doctor of Pharmacy program. Dr. Wang encourages aspiring researchers to stay curious, maintain dedication, and be open to alternative approaches if initial results don't meet expectations. 

If you found this information helpful, you might also enjoy exploring more topics related to cancer research and treatment at pcom.edu/research.